ArticleMedChemComm2018
Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[
Jingying Qiu, Wang Chen, Yanfei Jiang, Jing Chen, Yinpeng Zhang, Xiaoke Gu
Abstract read
In one paragraphArticle in MedChemComm, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Jingying QiuJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy , Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Xuzhou Medical University , Xuzhou 221004 , People's Republic of China . Email: gu_xk@xzhmu.edu.cn ; ; Tel: +86 516 83262137.
Wang ChenJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy , Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Xuzhou Medical University , Xuzhou 221004 , People's Republic of China . Email: gu_xk@xzhmu.edu.cn ; ; Tel: +86 516 83262137.
Yanfei JiangJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy , Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Xuzhou Medical University , Xuzhou 221004 , People's Republic of China . Email: gu_xk@xzhmu.edu.cn ; ; Tel: +86 516 83262137.
Jing ChenJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy , Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Xuzhou Medical University , Xuzhou 221004 , People's Republic of China . Email: gu_xk@xzhmu.edu.cn ; ; Tel: +86 516 83262137.
Yinpeng ZhangJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy , Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Xuzhou Medical University , Xuzhou 221004 , People's Republic of China . Email: gu_xk@xzhmu.edu.cn ; ; Tel: +86 516 83262137.
Xiaoke GuJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy , Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Xuzhou Medical University , Xuzhou 221004 , People's Republic of China . Email: gu_xk@xzhmu.edu.cn ; ; Tel: +86 516 83262137.ORCID 0000-0002-9831-108X Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Multidrug resistance (MDR) and metastasis are major causes of mortality in patients with cancer. We recently reported a bifendate derivative bearing a dibenzo[
Identifiers
PMID30542532
PMCPMC6247821
What OpenQuestion holds
Textmetadata
Read underepoch 390